Home・Aktien・Novavax Inc

Novavax Inc

Geschlossen

BrancheGesundheitswesen

7.94 2.72

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.9

Max

8.01

Schlüsselkennzahlen
By Trading Economics
Einkommen	-27M -9.5M
Verkäufe	-7.6M 140M
KGV Branchendurchschnitt	3.112 68.51
EPS	-0.06
Gewinnspanne	-6.803
Angestellte	749
EBITDA	-29M -543K

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+66.67% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-102M 1.2B
Vorheriger Eröffnungskurs	5.22
Vorheriger Schlusskurs	7.94

Nachrichtenstimmung

By Acuity

50%

116 / 340 Ranking in Healthcare

Novavax Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Aug. 2026, 19:36 UTC

News

Novavax Inc shares are higher today, supported by $57 million in second-quarter revenue and ongoing discussions with Sanofi on a COVID-19/influenza vaccine.

6. Aug. 2026, 23:01 UTC

News

Novavax Inc expects 2026 revenue of $235 million to $275 million. Shares are trading higher in after-market hours following the earnings call.

5. Aug. 2026, 23:01 UTC

Novavax shares are higher in after-market trading, though they remain below the 20-day moving average amid weaker-than-expected U.S. job growth data.

4. Aug. 2026, 23:36 UTC

Novavax Inc. shares are higher in after-market trading, despite remaining below their 20-day moving average. Broader market sentiment may support this upward movement.

3. Aug. 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31. Juli 2026, 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30. Juli 2026, 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29. Juli 2026, 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28. Juli 2026, 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27. Juli 2026, 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24. Juli 2026, 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23. Juli 2026, 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22. Juli 2026, 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21. Juli 2026, 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20. Juli 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Peer-Vergleich

Kursveränderung

Novavax Inc Prognose

Kursziel

By TipRanks

66.67% Vorteil

12-Monats-Prognose

Durchschnitt 13.25 USD 66.67%

Hoch 19 USD

Tief 7 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novavax Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Novavax Inc – Dist abgegeben haben.

Stimmung

By Acuity

116 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.